Neoadjuvant chemoradiotherapy combined with immunotherapy for locally advanced rectal cancer: A new era for anal preservation
Y Wang, L Shen, J Wan, H Zhang, R Wu… - Frontiers in …, 2022 - frontiersin.org
For locally advanced (T3-4/N+ M0) rectal cancer (LARC), neoadjuvant chemoradiotherapy
(nCRT) followed by total mesorectal excision (TME) is the standard treatment. It was …
(nCRT) followed by total mesorectal excision (TME) is the standard treatment. It was …
Radioimmunotherapy in colorectal cancer treatment: present and future
J Shi, Z Sun, Z Gao, D Huang, H Hong… - Frontiers in Immunology, 2023 - frontiersin.org
Colorectal cancer (CRC) is a deadly form of cancer worldwide. Patients with locally
advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational …
advanced rectal cancer and metastatic CRC have a poor long-term prognosis, and rational …
Combining radiation and the ATR inhibitor berzosertib activates STING signaling and enhances immunotherapy via inhibiting SHP1 function in colorectal cancer
C Liu, X Wang, W Qin, J Tu, C Li, W Zhao… - Cancer …, 2023 - Wiley Online Library
Abstract Background Immune checkpoint inhibitors (ICIs) targeting programmed cell death
protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown a moderate …
protein 1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) have shown a moderate …
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial
WW Xiao, G Chen, YH Gao, JZ Lin, XJ Wu, HL Luo… - Cancer Cell, 2024 - cell.com
Neoadjuvant chemoradiotherapy (NACRT) was the standard treatment for patients with
locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) proteins. In …
locally advanced rectal cancer (LARC) with proficient mismatch repair (pMMR) proteins. In …
Short-course radiotherapy combined with CAPOX and Toripalimab for the total neoadjuvant therapy of locally advanced rectal cancer: a randomized, prospective …
Y Wang, L Shen, J Wan, H Zhang, R Wu, J Wang… - BMC cancer, 2022 - Springer
Background For patients with locally advanced (T3-4/N+) rectal cancer (LARC), the standard
treatment is neoadjuvant chemoradiotherapy combined with total mesorectal resection …
treatment is neoadjuvant chemoradiotherapy combined with total mesorectal resection …
[HTML][HTML] Phase II study of capecitabine-based concomitant chemoradiation followed by durvalumab as a neoadjuvant strategy in locally advanced rectal cancer: the …
E Grassi, C Zingaretti, E Petracci, J Corbelli, G Papiani… - ESMO open, 2023 - Elsevier
Background This study investigated the efficacy of chemoradiotherapy (CRT) followed by
durvalumab as neoadjuvant therapy of locally advanced rectal cancer. Patients and …
durvalumab as neoadjuvant therapy of locally advanced rectal cancer. Patients and …
Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer
Background Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced
rectal cancer, with modest benefits on tumor regression and survival. Since …
rectal cancer, with modest benefits on tumor regression and survival. Since …
Emerging evidence of immunotherapy for colorectal cancer
Y Miyamoto, K Ogawa, M Ohuchi… - Annals of …, 2023 - Wiley Online Library
Since the advent of immune checkpoint inhibitors, which modulate the interplay between the
tumor cell and immune system, immunotherapy has become widely recognized as a new …
tumor cell and immune system, immunotherapy has become widely recognized as a new …
Meta-analysis of neoadjuvant immunotherapy for non-metastatic colorectal cancer
L Zhou, XQ Yang, G Zhao, F Wang, X Liu - Frontiers in Immunology, 2023 - frontiersin.org
Background Immunotherapy has been approved for the treatment of metastatic colorectal
cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non …
cancer. The efficacy and safety of neoadjuvant immunotherapy for the treatment of non …
Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus …
Background Long course radiotherapy plus neoadjuvant chemotherapy followed by
resection (total mesorectal excision, TME) has accepted widespread recognized in the …
resection (total mesorectal excision, TME) has accepted widespread recognized in the …